Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04262466 · ClinicalTrials.gov registry record · Phase 1
Safety and Efficacy of IMC-F106C as a Single Agent and in Combination With Checkpoint Inhibitors
A Phase 1 study of Select Advanced Solid Tumors, sponsored by Immunocore.
- Active
- Registry status
- Phase 1
- Development phase
- 410
- Enrollment target
- 20
- Study locations
NCT04262466 is a Phase 1 study of Select Advanced Solid Tumors that is active but no longer recruiting, run by Immunocore. The registered enrollment target is 410 participants. The trial reports 20 study locations across 15 states.
The verdict
NCT04262466, a Phase 1 study of Select Advanced Solid Tumors, is active but no longer recruiting, sponsored by Immunocore.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 410 participants
- Enrollment target
- 20
- Study locations
Study Summary
Brenetafusp (IMC-F106C) is an immune-mobilizing monoclonal T cell receptor against cancer (ImmTAC ®) designed for the treatment of cancers positive for the tumor-associated antigen PRAME. This is a first-in-human trial designed to evaluate the safety and efficacy of brenetafusp in adult participants who have the appropriate HLA-A2 tissue marker and whose cancer is positive for PRAME.
Conditions Studied
Interventions
- DRUG Brenetafusp
- DRUG Brenetafusp and pembrolizumab
- DRUG Brenetafusp and chemotherapy
- DRUG Brenetafusp and monoclonal antibodies and chemotherapy
- DRUG Brenetafusp and tebentafusp
Study Locations (20)
California
- University of California - San Diego - La Jolla
- Angeles Clinic and Research Institute - Los Angeles
- University of California Davis Comprehensive Center - Sacramento
Pennsylvania
- Abramson Cancer Center of the University of Pennsylvania - Philadelphia
- Thomas Jefferson University Hospital - Philadelphia
- UPMC Hillman Cancer Center - Pittsburgh
New York
- Columbia University Medical Center - New York
- Memorial Sloan Kettering - New York
Colorado
- University of Colorado - Aurora
District of Columbia
- Georgetown University Medical Center - Washington D.C.
Florida
- Houston Lee Moffitt Cancer Center & Research Institute - Tampa
Illinois
- The University of Chicago Medical Center - Chicago
Iowa
- University of Iowa - Iowa City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 410 participants |
| Start Date | 2020-02-25 |
| Est. Completion | 2027-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04262466
The ClinicalTrials.gov registry entry for NCT04262466 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 410 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Immunocore, which has 8 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Select Advanced Solid Tumors appearing as the primary indexed condition, and to 5 interventions - of which Brenetafusp is the first listed.
NCT04262466 reports 20 study locations spanning 15 distinct geographic areas - top geographies include California, Pennsylvania, New York.
Frequently Asked Questions
What is clinical trial NCT04262466 about?
NCT04262466 is a clinical study titled "Safety and Efficacy of IMC-F106C as a Single Agent and in Combination With Checkpoint Inhibitors". Brenetafusp (IMC-F106C) is an immune-mobilizing monoclonal T cell receptor against cancer (ImmTAC ®) designed for the treatment of cancers positive for the tumor-associated antigen PRAME. This is a first-in-human trial designed to evaluate the safety and efficacy of brenetafusp in adult participants...
What is the current status of trial NCT04262466?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 410 participants. The study started on 2020-02-25. Estimated completion is 2027-12.
What conditions does trial NCT04262466 study?
This clinical trial studies the following conditions: Select Advanced Solid Tumors.
What interventions are being tested in trial NCT04262466?
The interventions under investigation include: Brenetafusp (DRUG), Brenetafusp and pembrolizumab (DRUG), Brenetafusp and chemotherapy (DRUG), Brenetafusp and monoclonal antibodies and chemotherapy (DRUG), Brenetafusp and tebentafusp (DRUG).
Who is sponsoring clinical trial NCT04262466?
This trial is sponsored by Immunocore, which has 8 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04262466 being conducted?
This trial has 20 study locations across California, Colorado, District of Columbia, Florida, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Select Advanced Solid Tumors
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Phase 1/2 Study of KSQ-004EX, Autologous Tumor Infiltrating Lymphocytes Engineered to Inactivate Genes Encoding SOCS1 and Regnase-1, in Patients With Select Advanced Solid Tumors
RECRUITING · Phase 1
-
First in Human Study of CDR404 in HLA-A*02:01 Participants With MAGE-A4 Expressing Solid Tumors
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.